151 related articles for article (PubMed ID: 30309658)
1. Downregulation of miR-223 and miR-19a induces differentiation and promotes recruitment of osteoclast cells in giant-cell tumor of the bone via the Runx2/TWIST-RANK/RANKL pathway.
Jiang ZY; Jiang JJ; Ma YS; Li HY; Shi W; Fu PL; Xu CF; Lu JZ; Fu D; Xu JG
Biochem Biophys Res Commun; 2018 Nov; 505(4):1003-1009. PubMed ID: 30309658
[TBL] [Abstract][Full Text] [Related]
2. The role of TWIST as a regulator in giant cell tumor of bone.
Singh S; Mak IW; Cowan RW; Turcotte R; Singh G; Ghert M
J Cell Biochem; 2011 Sep; 112(9):2287-95. PubMed ID: 21503964
[TBL] [Abstract][Full Text] [Related]
3. MiR-30a inhibits osteolysis by targeting RunX2 in giant cell tumor of bone.
Huang Q; Jiang Z; Meng T; Yin H; Wang J; Wan W; Cheng M; Yan W; Liu T; Song D; Chen H; Wu Z; Xu W; Li Z; Zhou W; Xiao J
Biochem Biophys Res Commun; 2014 Oct; 453(1):160-5. PubMed ID: 25264196
[TBL] [Abstract][Full Text] [Related]
4. MicroRNA-106b inhibits osteoclastogenesis and osteolysis by targeting RANKL in giant cell tumor of bone.
Wang T; Yin H; Wang J; Li Z; Wei H; Liu Z; Wu Z; Yan W; Liu T; Song D; Yang X; Huang Q; Zhou W; Xiao J
Oncotarget; 2015 Aug; 6(22):18980-96. PubMed ID: 26053181
[TBL] [Abstract][Full Text] [Related]
5. MicroRNA-16-5p Inhibits Osteoclastogenesis in Giant Cell Tumor of Bone.
Sang S; Zhang Z; Qin S; Li C; Dong Y
Biomed Res Int; 2017; 2017():3173547. PubMed ID: 28589137
[TBL] [Abstract][Full Text] [Related]
6. RANK signalling in bone lesions with osteoclast-like giant cells.
Won KY; Kalil RK; Kim YW; Park YK
Pathology; 2011 Jun; 43(4):318-21. PubMed ID: 21532526
[TBL] [Abstract][Full Text] [Related]
7. Investigation of FGFR2-IIIC signaling via FGF-2 ligand for advancing GCT stromal cell differentiation.
Singh S; Singh M; Mak IW; Turcotte R; Ghert M
PLoS One; 2012; 7(10):e46769. PubMed ID: 23071632
[TBL] [Abstract][Full Text] [Related]
8. PTHrP increases RANKL expression by stromal cells from giant cell tumor of bone.
Cowan RW; Singh G; Ghert M
J Orthop Res; 2012 Jun; 30(6):877-84. PubMed ID: 22102368
[TBL] [Abstract][Full Text] [Related]
9. CCAAT/enhancer binding protein beta is up-regulated in giant cell tumor of bone and regulates RANKL expression.
Ng PK; Tsui SK; Lau CP; Wong CH; Wong WH; Huang L; Kumta SM
J Cell Biochem; 2010 May; 110(2):438-46. PubMed ID: 20225273
[TBL] [Abstract][Full Text] [Related]
10. Expression and localization of extracellular matrix metalloproteinase inducer in giant cell tumor of bone.
Si AI; Huang L; Xu J; Kumta SM; Wood D; Zheng MH
J Cell Biochem; 2003 Aug; 89(6):1154-63. PubMed ID: 12898514
[TBL] [Abstract][Full Text] [Related]
11. TGF-β induced PAR-1 expression promotes tumor progression and osteoclast differentiation in giant cell tumor of bone.
Wang T; Jiao J; Zhang H; Zhou W; Li Z; Han S; Wang J; Yang X; Huang Q; Wu Z; Yan W; Xiao J
Int J Cancer; 2017 Oct; 141(8):1630-1642. PubMed ID: 28670703
[TBL] [Abstract][Full Text] [Related]
12. Siglec-15, a member of the sialic acid-binding lectin, is a novel regulator for osteoclast differentiation.
Hiruma Y; Hirai T; Tsuda E
Biochem Biophys Res Commun; 2011 Jun; 409(3):424-9. PubMed ID: 21586272
[TBL] [Abstract][Full Text] [Related]
13. Receptor-Activator of Nuclear KappaB Ligand Expression as a New Therapeutic Target in Primary Bone Tumors.
Yamagishi T; Kawashima H; Ogose A; Ariizumi T; Sasaki T; Hatano H; Hotta T; Endo N
PLoS One; 2016; 11(5):e0154680. PubMed ID: 27163152
[TBL] [Abstract][Full Text] [Related]
14. MiR-126-5p regulates osteoclast differentiation and bone resorption in giant cell tumor through inhibition of MMP-13.
Wu Z; Yin H; Liu T; Yan W; Li Z; Chen J; Chen H; Wang T; Jiang Z; Zhou W; Xiao J
Biochem Biophys Res Commun; 2014 Jan; 443(3):944-9. PubMed ID: 24360951
[TBL] [Abstract][Full Text] [Related]
15. Expression of osteoclast differentiation signals by stromal elements of giant cell tumors.
Atkins GJ; Haynes DR; Graves SE; Evdokiou A; Hay S; Bouralexis S; Findlay DM
J Bone Miner Res; 2000 Apr; 15(4):640-9. PubMed ID: 10780856
[TBL] [Abstract][Full Text] [Related]
16. Denosumab treated giant cell tumour of bone: a morphological, immunohistochemical and molecular analysis of a series.
Girolami I; Mancini I; Simoni A; Baldi GG; Simi L; Campanacci D; Beltrami G; Scoccianti G; D'Arienzo A; Capanna R; Franchi A
J Clin Pathol; 2016 Mar; 69(3):240-7. PubMed ID: 26338802
[TBL] [Abstract][Full Text] [Related]
17. Denosumab induces tumor reduction and bone formation in patients with giant-cell tumor of bone.
Branstetter DG; Nelson SD; Manivel JC; Blay JY; Chawla S; Thomas DM; Jun S; Jacobs I
Clin Cancer Res; 2012 Aug; 18(16):4415-24. PubMed ID: 22711702
[TBL] [Abstract][Full Text] [Related]
18. Molecular pathways involved in crosstalk between cancer cells, osteoblasts and osteoclasts in the invasion of bone by oral squamous cell carcinoma.
Quan J; Zhou C; Johnson NW; Francis G; Dahlstrom JE; Gao J
Pathology; 2012 Apr; 44(3):221-7. PubMed ID: 22406484
[TBL] [Abstract][Full Text] [Related]
19. Integrin αvβ3 and CD44 pathways in metastatic prostate cancer cells support osteoclastogenesis via a Runx2/Smad 5/receptor activator of NF-κB ligand signaling axis.
Gupta A; Cao W; Chellaiah MA
Mol Cancer; 2012 Sep; 11():66. PubMed ID: 22966907
[TBL] [Abstract][Full Text] [Related]
20. Phenotypic and molecular studies of giant-cell tumors of bone and soft tissue.
Lau YS; Sabokbar A; Gibbons CL; Giele H; Athanasou N
Hum Pathol; 2005 Sep; 36(9):945-54. PubMed ID: 16153456
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
